177 related articles for article (PubMed ID: 15008862)
21. Efficacy and safety of sclerotherapy with polidocanol foam in comparison with fluid sclerosant in the treatment of first-grade haemorrhoidal disease: a randomised, controlled, single-blind, multicentre trial.
Moser KH; Mosch C; Walgenbach M; Bussen DG; Kirsch J; Joos AK; Gliem P; Sauerland S
Int J Colorectal Dis; 2013 Oct; 28(10):1439-47. PubMed ID: 23775099
[TBL] [Abstract][Full Text] [Related]
22. Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.
Bossart S; Daneluzzi C; Cazzaniga S; Ramelet AA; Uthoff H; Seyed Jafari SM; Baumgartner M; Hunger RE; Heidemeyer K; Willenberg T
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):274-283. PubMed ID: 36196455
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results.
Hamel-Desnos C; Desnos P; Wollmann JC; Ouvry P; Mako S; Allaert FA
Dermatol Surg; 2003 Dec; 29(12):1170-5; discussion 1175. PubMed ID: 14725657
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
Rabe E; Otto J; Schliephake D; Pannier F
Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
[TBL] [Abstract][Full Text] [Related]
25. Comparison of efficacy and safety between foam sclerotherapy and conventional sclerotherapy: a controlled clinical trial.
Ukritmanoroat T
J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S35-40. PubMed ID: 21717876
[TBL] [Abstract][Full Text] [Related]
26. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins.
Leach BC; Goldman MP
Dermatol Surg; 2003 Jun; 29(6):612-4; discussion 615. PubMed ID: 12786704
[TBL] [Abstract][Full Text] [Related]
27. Pulsed-dye laser treatment of leg telangiectasia: with and without simultaneous sclerotherapy.
Goldman MP; Fitzpatrick RE
J Dermatol Surg Oncol; 1990 Apr; 16(4):338-44. PubMed ID: 2324370
[TBL] [Abstract][Full Text] [Related]
28. Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique.
Rao J; Goldman MP
Dermatol Surg; 2005 Jan; 31(1):19-22. PubMed ID: 15720090
[TBL] [Abstract][Full Text] [Related]
29. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
Todd KL; Wright DI;
Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535
[TBL] [Abstract][Full Text] [Related]
30. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study.
Kern P; Ramelet AA; Wütschert R; Hayoz D
J Vasc Surg; 2007 Jun; 45(6):1212-6. PubMed ID: 17467226
[TBL] [Abstract][Full Text] [Related]
31. Sclerosing foam in the treatment of varicose veins and telangiectases: history and analysis of safety and complications.
Frullini A; Cavezzi A
Dermatol Surg; 2002 Jan; 28(1):11-5. PubMed ID: 11991262
[TBL] [Abstract][Full Text] [Related]
32. Polidocanol versus glucose in the treatment of telangiectasia of the lower limbs (PG3T): Protocol for a randomized, controlled clinical trial.
Bertanha M; Camargo PA; Moura R; Yoshida WB; Pimenta RE; Mariúba JV; Alcantara GP; de Paula DR; Sobreira ML
Medicine (Baltimore); 2016 Sep; 95(39):e4812. PubMed ID: 27684809
[TBL] [Abstract][Full Text] [Related]
33. An analysis of 72% chromated glycerin used for sclerotherapy: sterility, potency, and cost after extended shelf life.
Ghaznavi AM; Nakamura M; Tepper D
Dermatol Surg; 2015 Jan; 41(1):121-5. PubMed ID: 25521102
[TBL] [Abstract][Full Text] [Related]
34. A comparative study between cryo-laser cryo-sclerotherapy and sclerotherapy in the treatment of telangiectasia and reticular veins: A randomized controlled trial.
Nasser MM; Ghoneim BM; Eldaly W; Elmahdy H
J Vasc Surg Venous Lymphat Disord; 2024 Jul; 12(4):101874. PubMed ID: 38522666
[TBL] [Abstract][Full Text] [Related]
35. The Australian polidocanol (aethoxysklerol) study. Results at 2 years.
Conrad P; Malouf GM; Stacey MC
Dermatol Surg; 1995 Apr; 21(4):334-6; discussion 337-8. PubMed ID: 7728486
[TBL] [Abstract][Full Text] [Related]
36. Polidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial.
Bertanha M; Sobreira ML; Pinheiro Lúcio Filho CE; de Oliveira Mariúba JV; Farres Pimenta RE; Jaldin RG; Moroz A; Moura R; Rollo HA; Yoshida WB
Trials; 2014 Dec; 15():497. PubMed ID: 25527165
[TBL] [Abstract][Full Text] [Related]
37. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection.
Moreno-Moraga J; Hernández E; Royo J; Alcolea J; Isarría MJ; Pascu ML; Smarandache A; Trelles M
Lasers Med Sci; 2013 May; 28(3):925-33. PubMed ID: 22886138
[TBL] [Abstract][Full Text] [Related]
38. Sclerotherapy in tumescent anesthesia of reticular veins and telangiectasias.
Ramelet AA
Dermatol Surg; 2012 May; 38(5):748-51. PubMed ID: 22268802
[TBL] [Abstract][Full Text] [Related]
39. Polidocanol (aethoxysklerol) for sclerotherapy of superficial venules and telangiectasias.
Goldman PM
J Dermatol Surg Oncol; 1989 Feb; 15(2):204-9. PubMed ID: 2644330
[TBL] [Abstract][Full Text] [Related]
40. Polidocanol foam stability in terms of its association with glycerin.
Rial R; Hervas LS; Monux G; Galindo A; Martin A; Hernando M; Martinez I; Hernando A; Serrano FJ
Phlebology; 2014 Jun; 29(5):304-9. PubMed ID: 23470491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
